Zevra Therapeutics (ZVRA) AI Stock Analysis

• Market Cap: $467.51M
• Dividend Yield: N/A
• Average Volume (3M): 532.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.91
• Revenue Growth: 44.92%
• EPS Growth: -40.06%
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 54,679,640
• 10 Day Avg. Volume: 446,780
• 30 Day Avg. Volume: 532,390
• PEG Ratio: -0.35
• Price to Book (P/B): 11.42
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.66
• Enterprise Value/Market Cap: 1.07
• Enterprise Value/Revenue: 4.41
• Enterprise Value/Gross Profit: 15.56
• Enterprise Value/Ebitda: -1.81
• 1Y Price Target: $22.43
• Price Target Upside: 162.34% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 54 Neutral
• Price Target: $9.00 ▲(5.26%Upside)

Zevra Therapeutics' overall score is primarily influenced by strong revenue growth but is hampered by significant profitability and leverage issues. Technical indicators show positive momentum, yet caution is advised due to potential overbought conditions. The valuation remains challenging with ongoing losses, and while the earnings call highlighted strategic progress, market penetration challenges persist.

Positive Factors

FDA approval

FDA approval of Miplyffa for Niemann-Pick disease type C marked the first FDA-approved therapy for NPC.

Financial performance

Zevra reported net revenue of $20.4M, beating consensus and forecast, with Miplyffa generating $17.1M in net revenue.

Negative Factors

Olpruva performance

Olpruva's revenue remains modest despite a strategy focused on targeting adult patients with reimbursement challenges.

Patient adoption data

ZVRA did not provide a specific number to our question on how many patients are on the product and what fraction might be 'paid patients'.

Zevra Therapeutics Business Overview & Revenue Model

Company Description

Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

How the Company Makes Money

Zevra Therapeutics makes money through a revenue model centered on the development and commercialization of its proprietary drug candidates. The company generates revenue primarily through the sale of its approved therapies and milestone payments from collaboration and licensing agreements with other pharmaceutical companies. Additionally, Zevra Therapeutics may receive royalty payments based on sales of its licensed products. Strategic partnerships and collaborations play a significant role in the company's earnings, providing additional funding for research and development, as well as expanding the reach of its products in global markets.

Zevra Therapeutics Financial Statement Overview

Summary

Zevra Therapeutics shows strong revenue growth; however, it struggles with profitability and high leverage. The negative net profit and EBIT margins, coupled with a high debt-to-equity ratio and substantial cash outflows, highlight significant financial challenges.

Income Statement

The company exhibited a strong revenue growth rate of 71.86% TTM (Trailing-Twelve-Months), indicating robust top-line expansion. However, it faces challenges with profitability, as evidenced by a negative net profit margin of -226.67% TTM and a negative EBIT margin of -177.09% TTM. These negative margins reflect significant operational and financial hurdles in achieving profitability.

Balance Sheet

The debt-to-equity ratio stands at 1.51 TTM, signaling a high leverage position which could pose financial risks. The company's equity ratio of 23.76% TTM is relatively low, indicating a reliance on debt financing. Additionally, the return on equity (ROE) is negative at -224.26% TTM, reflecting substantial losses relative to shareholder equity.

Cash Flow

The free cash flow is negative at -$61.82 million TTM, with a free cash flow growth rate of 11.26%, suggesting moderate improvement. The operating cash flow to net income ratio is 0.67 TTM, indicating some alignment between operational performance and reported earnings, albeit with negative cash flow.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
40.59M	23.61M	27.46M	10.46M	28.65M	13.29M
	Gross Profit
32.00M	16.20M	24.52M	10.12M	26.59M	11.98M
	EBIT
-71.88M	-87.00M	-49.60M	-24.84M	7.73M	-4.78M
	EBITDA
-67.37M	-76.40M	-48.60M	-25.53M	-7.89M	-5.43M
	Net Income Common Stockholders
-91.99M	-105.51M	-46.05M	-41.54M	-8.55M	-12.76M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
37.34M	69.50M	43.05M	82.85M	112.35M	4.21M
	Total Assets
172.71M	178.13M	172.33M	115.53M	132.94M	11.21M
	Total Debt
61.84M	60.30M	43.77M	14.12M	1.59M	70.35M
	Net Debt
24.50M	26.51M	716.00K	-51.34M	-110.76M	66.14M
	Total Liabilities
131.69M	138.46M	110.46M	29.72M	5.82M	77.62M
	Stockholders Equity
41.02M	39.67M	61.86M	85.81M	127.12M	-66.41M
Cash Flow		Free Cash Flow
-61.82M	-69.67M	-33.83M	-18.81M	10.34M	-1.97M
	Operating Cash Flow
-61.72M	-69.67M	-33.53M	-18.72M	10.44M	-1.94M
	Investing Cash Flow
-26.41M	-22.16M	-17.39M	-36.72M	-15.52M	-33.00K
	Financing Cash Flow
82.50M	82.11M	28.46M	8.35M	113.11M	2.74M

Zevra Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.55
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZVRA, the sentiment is Positive. The current price of 8.55 is above the 20-day moving average (MA) of 8.24, above the 50-day MA of 7.70, and above the 200-day MA of 7.98, indicating a bullish trend. The MACD of 0.28 indicates Negative momentum. The RSI at 59.19 is Neutral, neither overbought nor oversold. The STOCH value of 49.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZVRA.

Zevra Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MAZE	59 Neutral	$533.01M	―		―	―	―
ZVRA	54 Neutral	$467.51M	―	-204.78%	―	44.92%	-40.06%
Sector *	53 Neutral	$5.22B	3.32	-45.04%	2.83%	16.81%	-0.27%
UPB	48 Neutral	$502.97M	―		―	―	―
RLAY	44 Neutral	$528.05M	―	-45.46%	―	-78.26%	15.41%
OMER	40 Underperform	$194.53M	―	87.26%	―	―	-43.76%
SION		$622.60M	―		―	―	―

Zevra Therapeutics Corporate Events

Zevra Therapeutics Elects New Directors at Annual Meeting

On May 29, 2025, Zevra Therapeutics held its Annual Meeting of Stockholders where Wendy Dixon, Ph.D., and Tamara A. Favorito were elected as directors. The meeting also saw the ratification of Ernst & Young LLP as the independent public accounting firm for the fiscal year ending December 31, 2025. The election process was marked by the disqualification of nominees proposed by stockholder Daniel J. Mangless due to non-compliance with legal requirements and company bylaws, ensuring the election of the company’s preferred candidates.

The most recent analyst rating on (ZVRA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Zevra Therapeutics stock, see the ZVRA Stock Forecast page.